Stock WBIO WPD PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 09:49:31 2022-06-28 am EDT 		5-day change 1st Jan Change
0.045 CAD -.--% Intraday chart for WPD Pharmaceuticals Inc. -.--% -.--%
Feb. 05 WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Feb. 02 WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI

Business Summary

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.

Number of employees: 16

Managers

Managers TitleAgeSince
Mariusz Olejniczak CEO
 Chief Executive Officer 49 -
Katarzyna Suchoszek COO
 Chief Operating Officer - -
Agnieszka Czyzewska-Buczynska CTO
 Chief Tech/Sci/R&D Officer - -
Marek Sipowicz CTO
 Chief Tech/Sci/R&D Officer - 20-10-14
Beata Pajak CTO
 Chief Tech/Sci/R&D Officer - -

Members of the board

Members of the board TitleAgeSince
Romuald Harwas BRD
 Director/Board Member 52 22-02-01
Teresa Lilian Rzepczyk BRD
 Director/Board Member 49 19-04-22
Peter Novak BRD
 Director/Board Member 66 20-01-07
Nicholas Luksha BRD
 Director/Board Member 43 23-04-30
Constantine Carmichel BRD
 Director/Board Member - 23-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 113,438,244 67,341,918 ( 59.36 %) 0 59.36 %

Shareholders

NameEquities%Valuation
Constantine Carmichel
1.939 %
2,200,000 1.939 % 72 600 $

Company contact information

WPD Pharmaceuticals, Inc.

750 West Pender Street Suite 401

V6C 2T7, Vancouver

+604 561 2687

http://www.wpdpharmaceuticals.com
address WPD Pharmaceuticals Inc.(WBIO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WPD PHARMACEUTICALS INC. Stock WPD Pharmaceuticals Inc.
-.--% 3.73M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. WBIO Stock
  4. Company WPD Pharmaceuticals Inc.